Abstract
The value of innovation in medicines is clear. Despite all of the progress in the twenty-first century, there are still many unmet medical needs and opportunities to improve healthcare. The challenges for pharmaceutical companies include ways in which to stay competitive and flexible in an environment of constant knowledge growth and increasingly sophisticated technologies, and ways to generate sufficient revenues to sustain their own growth. To that end, pharmaceutical companies are compelled to adapt different business models in the face of new challenges. The industry is plagued with long research and development (R&D) cycles and low success rates for innovative treatments; something has to change. The need to collaborate externally across the process of discovery, development, manufacturing and commercialization is a must. Furthermore, collaborations have increased in frequency and scope, expanding the opportunities to access global scientific talent in academia, research institutes and biotechnology companies. Despite the perception that pharma companies are ‘closed’ or tightly controlled industries, open innovation is already well established in the pharmaceutical sector and used to supplement R&D in the process of bringing new medicines for patients faster, and at a lower cost. Over the years, each pharma company has tailored the open-innovation concept to develop its own model based on particular needs and offerings. Independently of the model, the creation of successful partnerships in external innovation requires reaching out and connecting beyond the traditional organizational boundaries. Substantial internal cultural changes are required to implement open-innovation strategies that should co-exist without competing with the traditional ways of operating. Major changes bring challenges but create multiple opportunities for scientists and organizations. High-quality drug discovery requires continuous learning and an open way of thinking to adopt novel operational models and to implement efficient collaborations.
Similar content being viewed by others
References
Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today. 2012;17(19–20):1088–102.
Melese T, Lin SM, Chang JL, Cohen NH. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat Med. 2009;15(5):502–7.
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203–14.
Chesbrough HW. Open innovation: the new imperative for creating and profiting from technology. 1st ed. Boston: Harvard Business School Press; 2003.
Chesbrough HW, Bogers M. Explicating open innovation: clarifying an emerging paradigm for understanding innovation. New Frontiers in Open Innovation. 1st ed. Oxford: Oxford University Press; 2014. p. 3–28.
Reichman M, Simpson PB. Open innovation in early drug discovery: roadmaps and roadblocks. Drug Discov Today. 2016;21(5):779–88.
Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A. Drug discovery: new models for industry-academic partnerships. Drug Discov Today. 2009;14(1–2):95–101.
Nilsson N, Minssen T. Unlocking the full potential of open innovation in the life sciences through a classification system. Drug Discov Today. 2018;23(4):771–5.
Holmes D, Ashour M. A new chapter in innovation. Nature. 2016;533(7602):S54–5.
Schuhmacher A, Gassmann O, McCracken N, Hinder M. Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? J Transl Med. 2018;16:119.
Schuhmacher A, Germann PG, Trill H, Gassmann O. Models for open innovation in the pharmaceutical industry. Drug Discov Today. 2013;18(23–24):1133–7.
Bentzien J, Bharadwaj R, Thompson DC. Crowdsourcing in pharma: a strategic framework. Drug Discov Today. 2015;20(7):874–83.
Renwick MJ, Mossialos E. Crowdfunding our health: economic risks and benefits. Soc Sci Med. 2017;191:48–56.
Mittleman B, Neil G, Cutcher-Gershenfeld J. Precompetitive consortia in biomedicine—how are we doing? Nat Biotechnol. 2013;31(11):979–85.
Vaudano E. The innovative medicines initiative: a public private partnership model to foster drug discovery. Comput Struct Biotechnol J. 2013;6(7):e201303017.
Liang BA, Mackey T. Public-private partnerships to promote biosimilar access, affordability, and patient safety in emerging markets. Stanf J Law Sci Policy. 2014;7:1–9.
Bingham A, Spradlin D. The challenge driven enterprise. The open innovation marketplace: creating value in the challenge driven enterprise. 6th ed. Upper Saddle River: FT Press; 2011. p. 117–38.
Hossain M. Performance and potential of open innovation intermediaries. Proc Soc Behav Sci. 2012;58:754–64.
Kar S. Open innovation: an answer for neglected diseases. Future Med Chem. 2010;2(9):1411–5.
Moran M. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med. 2005;2(9):e302.
McCoy D, Kembhavi G, Patel J, Luintel A. The Bill & Melinda Gates Foundation’s grant-making programme for global health. Lancet. 2009;373:1645–53.
Alcalay RN, Aasly J, Berg D, Bressman S, Brice A, Brockmann K, Michael J Fox Foundation Consortium, et al. Geographical differences in returning genetic research data to study participants. Genet Med. 2014;16(8):644–5.
Schwartz K, Huff B. The story of Eli Lilly’s open innovation journey—How one company developed a mature model. Visions. 2010;34(1):19–22.
Owens PK, Raddad E, Miller JW, Stille JR, Olovich KG, Smith NV, et al. A decade of innovation in pharmaceutical R&D: the Chorus model. Nature. 2015;14(1):17–28.
Steadman VA. Drug discovery: collaborations between contract research organizations and the pharmaceutical industry. ACS Med Chem Lett. 2018;9(7):581–3.
Lee JA, Hu SC, Willard FS, Cox KL, Galvin RJS, Peery RB, et al. Open innovation for phenotypic drug discovery: the PD2 assay panel. J Biomol Screen. 2011;16(6):588–602.
Lee JA, Berg EL. Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches. J Biomol Screen. 2013;18(10):1143–55.
Alvim-Gaston M, Grese T, Mahoui A, Palkowitz AD, Pineiro-Nunez M, Watson I. Open Innovation drug discovery (OIDD): a potential path to novel therapeutic chemical space. Curr Top Med Chem. 2014;14(3):294–303.
Nilsson N, Felding J. Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity. Future Med Chem. 2015;7(14):1853–9.
Birnbaum MJ. Pharma and academia: what we have here is a failure to communicate. Cell Metab. 2016;24(3):365–7.
Carroll GP, Srivastava S, Volini AS, Piñeiro-Núñez MM, Vetman T. Measuring the effectiveness and impact of an open innovation platform. Drug Discov Today. 2017;22(5):776–85.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for the preparation of this manuscript.
Conflict of interest
Maria Angeles Martinez-Grau and Maria Alvim-Gaston are full-time employees of Eli Lilly and Company. The opinions expressed in this article are the personal views of the authors.
Rights and permissions
About this article
Cite this article
Martinez-Grau, M.A., Alvim-Gaston, M. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector. Pharm Med 33, 193–198 (2019). https://doi.org/10.1007/s40290-019-00280-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40290-019-00280-5